H.C. Wainwright lowered the firm’s price target on Mainz Biomed to $3 from $5 and keeps a Buy rating on the shares after the company announced a partnership with Trusted Health Advisors to support its U.S. launches and management of commercial program for diagnostic products. The firm believes Mainz may need to raise additional capital to complete the U.S. pivotal trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed partners with Trusted Health Advisors
- Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
- MYNZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mainz Biomed to showcase ColoAlert at Gynecology Conference
- Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community